Showing results (131-140 of 208) with videos related to

Sort By:
Pageof 21
Oncoimmunology|January 12, 2023
RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignanciesCamille Bigenwald, Yacine Haddad, Cassandra Thelemaque, et al.
Haematologica|December 26, 2015
Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA studyMorgane Cheminant, Coralie Derrieux, Aurore Touzart, et al.
American Journal of Hematology|February 14, 2020
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphomaJohn Timmerman, Charles Herbaux, Vincent Ribrag, et al.
Blood|August 15, 2019
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087Robert Chen, Pier Luigi Zinzani, Hun Ju Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 26, 2017
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin LymphomaRobert Chen, Pier Luigi Zinzani, Michelle A Fanale, et al.
The Lancet. Oncology|October 9, 2020
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trialFranck Morschhauser, Hervé Tilly, Aristeidis Chaidos, et al.
Blood Advances|May 31, 2024
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosisAaron T Gerds, Claire Harrison, Jean-Jacques Kiladjian, et al.
Bone Marrow Transplantation|March 4, 2021
Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trialBenoit Tessoulin, David Chiron, Catherine Thieblemont, et al.
The Lancet. Haematology|August 8, 2020
Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 studyJean-Marie Michot, Reda Bouabdallah, Umberto Vitolo, et al.
Leukemia & Lymphoma|October 2, 2012
Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma NetworkMartin Dreyling, Hanneke C Kluin-Nelemans, Sílvia Beà, et al.
Pageof 21